Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ablevia Biotech GmbH has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, creating distinct channels for claim and prior-art analysis.
ALLEN, MICHAEL D is the busiest examiner, with 1 pending action. Counsel should coordinate the portfolio’s scientific position while tailoring each response to the applicable examiner’s practice.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | FISCHER, JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246117 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | ALLEN, MICHAEL D | 62d |
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246117 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | ALLEN, MICHAEL D | 1671 | §112 | Non-Final OA | 62d | Pending | Mar 21, 2023 |
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | FISCHER, JOSEPH | 1658 | §102§103§112Other | Non-Final OA | — | Pending | Mar 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAblevia Biotech GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Michael D Allen has the most, with 1 of Ablevia Biotech GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
